6533b856fe1ef96bd12b32a5

RESEARCH PRODUCT

Efficacy of rituximab as a single-agent therapy for the treatment of granulomatous and lymphocytic interstitial lung disease in patients with common variable immunodeficiency.

Alessandro De PellegrinRiccardo De CarliF. ReccardiniLorenzo CereserMarco De CarliBarbara FrossiRossano Girometti

subject

OncologyAdultMalemedicine.medical_specialtyMEDLINEYoung AdultText miningInternal medicinemedicineImmunology and AllergyHumansImmunologic FactorsSingle agentIn patientYoung adultbusiness.industryCommon variable immunodeficiencyInterstitial lung diseasemedicine.diseaseRespiratory Function TestsCommon Variable ImmunodeficiencyTreatment OutcomeRituximabFemalebusinessLung Diseases InterstitialRituximabmedicine.drug
yearjournalcountryeditionlanguage
2019-03-01The journal of allergy and clinical immunology. In practice
10.1016/j.jaip.2018.10.041https://pubmed.ncbi.nlm.nih.gov/30408616